Splenectomy and thrombosis: the case of thalassemia intermedia

Journal of Thrombosis and Haemostasis - Tập 8 - Trang 2152-2158 - 2010
A.T. TAHER1, K.M. MUSALLAM1, M. KARIMI2, A. EL‐BESHLAWY3, K. BELHOUL4, S. DAAR5, M. SANED4, C. CESARETTI6, M.D. CAPPELLINI6
1Department of Internal Medicine, Hematology‐Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
2Department of Pediatrics, Thrombosis and Hemostasis Unit, Hematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Pediatrics, Cairo University, Cairo, Egypt
4Genetic and Thalassemia Center, Al Wasl Hospital, Dubai, United Arab Emirates
5Sultan Qaboos University, Muscat, Oman
6Centro Anemie Congenite, Ospedale Maggiore Policlinico, IRCCS, Universitá di Milano, Milano, Italy

Tài liệu tham khảo

Weatherall, 2001

Rund, 2005, Beta‐thalassemia, N Engl J Med, 353, 1135, 10.1056/NEJMra050436

Sturgeon, 1955, Genetic and biochemical studies of intermediate types of Cooley’s anaemia, Br J Haematol, 1, 264, 10.1111/j.1365-2141.1955.tb05509.x

Taher, 2010, Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study, Blood, 115, 1886, 10.1182/blood-2009-09-243154

Borgna Pignatti, 1998, Thromboembolic events in beta thalassemia major: an Italian multicenter study, Acta Haematol, 99, 76, 10.1159/000040814

Taher, 2006, Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran, Thromb Haemost, 96, 488, 10.1160/TH06-05-0267

Taher, 2008, Thalassemia and hypercoagulability, Blood Rev, 22, 283, 10.1016/j.blre.2008.04.001

Crary, 2009, Vascular complications after splenectomy for hematologic disorders, Blood, 114, 2861, 10.1182/blood-2009-04-210112

Camaschella, 1995, Thalassemia intermedia, Haematologica, 80, 58

Barst, 2004, Diagnosis and differential assessment of pulmonary arterial hypertension, J Am Coll Cardiol, 43, 40S, 10.1016/j.jacc.2004.02.032

Kleber, 1992, Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial, Br Heart J, 67, 289, 10.1136/hrt.67.4.289

Nathan, 2009, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 32, 193, 10.2337/dc08-9025

Cadili, 2008, Complications of splenectomy, Am J Med, 121, 371, 10.1016/j.amjmed.2008.02.014

Shinar, 1989, Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia, J Clin Invest, 83, 404, 10.1172/JCI113898

Hershko, 1978, Non‐specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity, Br J Haematol, 40, 255, 10.1111/j.1365-2141.1978.tb03662.x

Tavazzi, 2001, Membrane‐bound iron contributes to oxidative damage of beta‐thalassaemia intermedia erythrocytes, Br J Haematol, 112, 48, 10.1046/j.1365-2141.2001.02482.x

Borenstain‐Ben Yashar, 1993, Phosphatidylserine in the outer leaflet of red blood cells from beta‐thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes, Am J Hematol, 44, 63, 10.1002/ajh.2830440114

Helley, 1996, Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta‐thalassemia, Thromb Haemost, 76, 322, 10.1055/s-0038-1650577

Atichartakarn, 2002, Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta‐thalassaemic patients, Br J Haematol, 118, 893, 10.1046/j.1365-2141.2002.03711.x

Habib, 2008, Elevated levels of circulating procoagulant microparticles in patients with beta‐thalassemia intermedia, Haematologica, 93, 941, 10.3324/haematol.12460

Aessopos, 2007, Thalassemia intermedia today: should patients regularly receive transfusions?, Transfusion, 47, 792, 10.1111/j.1537-2995.2007.01192.x

Pippard, 1988, Iron balance and the management of iron overload in beta‐thalassemia intermedia, Birth Defects Orig Artic Ser, 23, 29

Pootrakul, 2003, Clinical trial of deferiprone iron chelation therapy in beta‐thalassaemia/haemoglobin E patients in Thailand, Br J Haematol, 122, 305, 10.1046/j.1365-2141.2003.04412.x

Voskaridou, 2010, Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study, Br J Haematol, 148, 332, 10.1111/j.1365-2141.2009.07930.x

Del Principe, 1993, PADGEM/GMP‐140 expression on platelet membranes from homozygous beta thalassaemic patients, Br J Haematol, 84, 111, 10.1111/j.1365-2141.1993.tb03033.x

Ruf, 1997, In‐vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta‐thalassaemia major, Br J Haematol, 98, 51, 10.1046/j.1365-2141.1997.1502965.x

Eldor, 1991, In vivo platelet activation in beta‐thalassemia major reflected by increased platelet‐thromboxane urinary metabolites, Blood, 77, 1749, 10.1182/blood.V77.8.1749.1749

Cappellini, 2005, Coagulation and splenectomy: an overview, Ann N Y Acad Sci, 1054, 317, 10.1196/annals.1345.039

Gladwin, 2008, Pulmonary complications of sickle cell disease, N Engl J Med, 359, 2254, 10.1056/NEJMra0804411

Isma’eel, 2008, Relation between iron‐overload indices, cardiac echo‐Doppler, and biochemical markers in thalassemia intermedia, Am J Cardiol, 102, 363, 10.1016/j.amjcard.2008.03.066

O’Donnell, 2007, Age‐related changes in adaptation to severe anemia in childhood in developing countries, Proc Natl Acad Sci USA, 104, 9440, 10.1073/pnas.0703424104

Aessopos, 2001, Cardiac involvement in thalassemia intermedia: a multicenter study, Blood, 97, 3411, 10.1182/blood.V97.11.3411

Aessopos, 2005, Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia, Chest, 127, 1523, 10.1378/chest.127.5.1523